Virax Biolabs Group (VRAX) news
Recent news
Virax Biolabs Group Limited announces exercise of preferred investment options for $3.3 million gross proceeds
Virax Biolabs Group Limited (Nasdaq: VRAX) announced on July 9, 2026, that it has received gross proceeds of $3.3 million from the exercise of preferred investment options issued in a prior private placement. The exercise of these options is part of the company’s ongoing capital-raising efforts and…
AInvest Wire · Jul 9, 2026Virax Biologics signs multi-country commercial supply agreement with Fosun Diagnostics
Virax Biolabs Group Limited (NASDAQ: VRAX) has entered into a multi-country commercial supply agreement with Fosun Diagnostics, expanding its global reach for the distribution of its diagnostic products. Under the terms of the agreement, Fosun Diagnostics will supply Virax’s ImmuneSelect and…
AInvest Wire · Jul 9, 2026Virax Biolabs Group Ltd - announces 1-for-25 share consolidation
AInvest Wire · Jun 24, 2026Virax Biolabs looks to raise $5M via stock offering
AInvest Wire · Aug 22, 2024Virax surges amid bird flu concerns
Virax surges amid bird flu concerns Virax Biolabs (VRAX) experienced a remarkable surge in its stock price following growing attention to the company as a leading provider of avian influenza tests [1]. The rise in Virax's shares is not without merit, as the global bird flu outbreak continues to…
AInvest Wire · Jun 6, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.